ICMJE DISCLOSURE FORM

Date: _	Decen	nber 20 th , 2021		
Your N	lame:	Timothy Price		
Manus	cript Title:_	The evolving l	landscape of BRAF Inhibitors in BRAF Mutant Colorectal Ca	ancer and the
<u>added</u>	l Value of (Cytotoxic Chemot	therapy therapy the state of th	
Manus	cript numb	er (if known):	DMR-21-99	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	x None	
3	Royalties or licenses	x None	
4	Consulting fees	x None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	x None
6	Payment for expert	x None
	testimony	
7	Support for attending meetings and/or travel	xNone
8	Patents planned, issued or	x None
8	pending	
9	Participation on a Data Safety Monitoring Board or	xNone
	Advisory Board	
10	Leadership or fiduciary role in other board, society,	xNone
	committee or advocacy group, paid or unpaid	
11	Stock or stock options	xNone
12	Receipt of equipment, materials, drugs, medical	x None
	writing, gifts or other services	
13	Other financial or non-	x None
	financial interests	
	ase summarize the above co	nflict of interest in the following box:

Please place an "X" next to the following statement to indicate your agreement:

__x__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date:	December 20 ¹¹ , 2021	
Your Name	:Barbara Geerinckx	<u> </u>
Manuscript	:Title: The evolving la	ndscape of BRAF Inhibitors in BRAF Mutant Colorectal Cancer and the
added Val	ue of Cytotoxic Chemoth	<u>erapy</u>
Manuscript	number (if known):	DMR-21-99

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastx None	36 months
3	Royalties or licenses	x None	
4	Consulting fees	x None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	x None
6	Payment for expert testimony	xNone
7	Support for attending meetings and/or travel	xNone
8	Patents planned, issued or pending	xNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	xNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	xNone
11	Stock or stock options	x None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	xNone
13	Other financial or non- financial interests	xNone
	ase summarize the above co	nflict of interest in the following box:

Please place an "X" next to the following statement to indicate your agreement:

__x__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: _	Dec	ember 20 ^{tn} , 2021					
Your N	ame:	Annabel Smith	<u>—</u>				
Manus	cript Title:	The evolving landsca	ape of BRAF Inhi	bitors in BR	AF Mutant Co	olorectal Ca	ncer and the
<u>added</u>	Value of	Cytotoxic Chemotherap	<u>V</u>				
Manus	cript numb	per (if known): DMR	k-21-99				
	-						

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	x None	
3	Royalties or licenses	xNone	
4	Consulting fees	x None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	x None
6	Payment for expert	x None
	testimony	
7	Support for attending meetings and/or travel	xNone
8	Patents planned, issued or	x None
8	pending	
9	Participation on a Data Safety Monitoring Board or	xNone
	Advisory Board	
10	Leadership or fiduciary role in other board, society,	xNone
	committee or advocacy group, paid or unpaid	
11	Stock or stock options	xNone
12	Receipt of equipment, materials, drugs, medical	x None
	writing, gifts or other services	
13	Other financial or non-	x None
	financial interests	
	ase summarize the above co	nflict of interest in the following box:

Please place an "X" next to the following statement to indicate your agreement:

__x__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.